Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Bioceros B.V. announces change of ownership


Utrecht, The Netherlands, February 17th, 2011 - Bioceros B.V. announces that it has successfully realized a change of ownership. This is the result of the purchase of the outstanding shares owned by Forbion, Thuja Capital and Biogeneration Ventures by existing shareholders and the management team.

Bioceros’ CEO, Dr. Bram Bout comments: “The financial round of 2008, which was led by Thuja Capital and Biogeneration Ventures, has allowed us to build a strong, independent service business and to lay the foundation for a product pipeline. We are therefore pleased and proud that we can offer our investors this exit. Bioceros will further grow its service business by expanding its technology platform and spin out its early-stage products in a separate legal entity.”

Dr. Mark de Boer (chairman) and Dr. Oscar Schoots, MBA, will remain members of the Supervisory Board of Bioceros.

About Bioceros.

Bioceros is a biotech company focusing on pre-clinical development of protein products, with an emphasis on monoclonal antibodies. Bioceros’ technology platform covers early pre-clinical development of monoclonal antibodies, including generation of monoclonal antibodies in mice, making high protein producing CHO and PER.C6® cell lines, assay development and pre-clinical manufacturing at 20L scale. This is all Quality Controlled, using state of the art serum-free culture media, such that the generated cell lines can be used for GMP manufacturing. Bioceros is preferred vendor of DSM Biologics and Crucell for PER.C6® cell line generation services.
Bioceros uses this technology platform to offer services to the industry and academia, and to develop its own pipeline of monoclonal antibody products.

Bioceros is located in Utrecht, the Netherlands. For more information, please visit www.bioceros.com or contact:


Remco M. Brandt
COO
Bioceros BV
Yalelaan 46
3584 CM UTRECHT
The Netherlands

Phone: +31(0) 30-253 7910
Cell: +31(0) 6-1012 7709
Fax: +31(0) 30-253 2288
URL: www.bioceros.com


Publisher Contact Information:

Bioceros
+31(0) 30-253 7910
-

Company profile of Bioceros
Past press releases of Bioceros.

Data


20,276
Tech investments
From our Online Data Service
13,080
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Jul 27N/AInternet commerce
Jul 27€55.0MInternet commerce
Jul 24€1.0MBiotechnology
Jul 23€33.0MBiotechnology
Jul 23€37.0MInternet commerce
Jul 22€2.2MBiotechnology
Jul 22N/ABiotechnology

For information on Europe's most extensive database on technology funding click here!

Events


BIO-Europe 2015
November 2 - 4, 2015

CONNECTIONS Europe
November 10 - 11, 2015


Press Releases


Jul 22
Wilson Therapeutics
wilson therapeutics announces the appointment of dr. carl bjartmar ...

Jul 16
Immunocore Ltd
immunocore secures $320 million (£205 million) in europe’s largest ...

Jul 15
Mailjet
iris capital leads series b round for email service provider mailjet

Jul 15
Credit Benchmark
credit benchmark raises $20m in series b financing led by balderton...

Jul 10
Autifony Therapeutics
autifony therapeutics extends series a with £8 million for hearing ...





About usContact usLegal Information
Copyright © 1999-2015
Emerging Technology Research Europe Inc. All rights reserved.